A useful additional tool in the evaluation of rheumatoid arthritis (RA) over recent years has been the simultaneous estimation of a number of blood components kniown to change in active disease and which provide an objective measure of disease activity. This work has been reviewed by Haatajal and Kendall.2 In addition it has been shown that improvement in the disease (i.e., a change in the course of the disease rather than symptomatic relief) is accompanied by a return towards normality in some of these systemic measurements such as the acute phase proteins, ESR,3 4 and serum sulphydryl levels.5
The present detailed study was designed to confirm the reported abnormalities in systemic measurements, to investigate whether changes in other systemic variables followed the course of the disease, and to establish the laboratory measurements which best correlate with clinical indices of disease activity during treatment with D-penicillamine. These measurements may well provide information not only as to the best laboratory test to apply as an objective measure of disease activity but also give Accepted for publication 24 July 1979 Correspondence to Dr M. E. Pickup insight into the pathogenesis of the disease and possible mechanisms of drug action.
Patients and methods

PATIENTS
Fifteen patients (12 female, mean age 52 6, range 36-66 years; 3 male, mean age 43 3, range 38-51 years) were included in the study. All had classical or definite RA (ARA criteria). In addition patients showed evidence of at least moderate disease activity as judged by the presence of at least 3 of the following 5 criteria: (a) tenderness of more than 6 joints; (b) swelling of more than 3 joints; (c) morning stiffness longer than 45 minutes; (d) articular index more than 20; (e) ESR more than 28 mm.hQ1.
None of the patients had received specific antirheumatoid drug therapy (e.g., gold, penicillamine, hydroxychloroquine) before the present study. Two patients were on prednisolone 1 * 5 mg daily and 7 mg daily respectively. Each patient agreed to participate after a full explanation had been given. T I ME(WEEKS} changes in an individual of initially comparable disease activity but who responded well (Fig. 3a) .
Correlation coefficients derived from individual patient data describing the interrelationship of individual systemic and clinical variables are available on request. The most notable correlations (all 
Discussion
The finding in RA patients of systemic variables displaced from normal has been previously reported; the present work confirms these findings. For example, low haemoglobin,l" creatinine and bilirubin,12 sulphydryl,"3 and histidine levels14 have been reported, while high levels have been recorded in the acute phase proteins and ESR,3 plasma viscosity,'5 platelet count,'6 alkaline phosphatase,17 gamma glutamyl transpeptidase,'8 white cell count and globulin,'2 immunoglobulins and RA latex. '9 20 Previous reports of low albumin levels2' were not confirmed in the present study. The use of a matched normal group for comparative purposes was necessary in view of previous reports of the dependence of many systemic variables on age and sex.' 1214 22 The observed delayed response to penicillamine (weeks [12] [13] [14] [15] [16] specific action' in that it seems to change the course of the disease.326 27 This change was observed in terms of a return towards normal levels in the acute phase proteins, i.e., fibrinogen, CRP, haptoglobin, and ESR (Fig. 2) . However, significant changes either towards normal or within the normal range were also recorded in plasma viscosity, alkaline phosphatase, gamma glutamyl transpeptidase, bilirubin, total protein, creatinine, white cell and platelet count, serum sulphydryl, serum histidine. plasma salicylate, IgM, and C3.
Not all these changes necessarily reflect improvement in disease activity. The mean white cell count dropped towards the lower end of the normal range between weeks 8 and 16; this may well have been a drug induced side effect. Similarly, the drop in platelet count may be a drug induced side effect, particularly as some individual counts were reduced towards the lower end of the accepted normal range. However, platelet counts at week 0, although within the literature quoted normal range, were high compared with the matched controls ( Table 2) . Thrombocytosis has been previously reported in RA,'6 and thus any reduction in count may reflect disease improvement rather than side effect. The increase in serum sulphydryl level during penicillamine therapy may be a result of one or more processes. Firstly, a direct action of penicillamine to increase protein sulphydryl levels may be responsible. This has been reported in vitro and suggests a possible mode of action of the drug. 28 Secondly, serum sulphydryl levels may increase as an indirect response to the therapeutic action of the drug. Studies in progress, estimating sulphydryl levels following therapy with 'non-thiol' drugs may clarify this situation.
The increase in serum histidine may also reflect either a direct action of the drug or nonspecific disease improvement. This has been recently discussed. 29 The reduction in salicylate level (Fig. 2) is not surprising in view of the patients' instructions to reduce the aspirin dose as they improved. Evidence of aspirin's failure to affect many other parameters 3 27 30 31 suggests that systemic changes are penicillamine-induced rather than a consequence of nonspecific anti-inflammatory drug treatment.
Haemoglobin levels provide one example in the present study of findings which differ from those hitherto reported. Although an upward trend was observed (Fig. 2) , the patients' anaemia failed to respond significantly to penicillamine treatment whereas previous reports have indicated significant improvement during treatment.25 32 (Table 3) indicate that IgG and IgM levels correlate with disease activity but they were not the most useful indices.
Our results have shown unequivocally a definite clinical and laboratory improvement with penicillamine. Moreover, they also suggest that the best discriminant laboratory indices are ESR and CRP. Some of these laboratory changes such as those in sulphydryl concentration may be fundamental to the process of rheumatoid arthritis rather than nonspecific accompaniments of the disease state. Our further studies, using alternative antirheumatoid drugs, should serve to distinguish those laboratory measurements which are specific to the disease process and those changes that are drug induced. In this way we may yet gain more insight into the basic nature of the pathological process in rheumatoid arthritis. 
